Clinical & Experimental Data.

Because the engineered rod carries far more active per unit, it delivers an equal dose using roughly one-hundredth of the material of a conventional spicule, and traces to the collagen (dermal) layer within 48 hours. Two-photon / confocal imaging, BN Material Science.

The clearest lesson is that an active ingredient is only as good as its ability to reach the cells that use it. In the Franz-cell work, the very same molecule crossed skin roughly three times better through an engineered spicule than in a strong penetration solvent — and thirty-seven times better than in water. Nothing about the molecule changed; only how it was carried. That reframed our whole formulation philosophy. We do not chase novelty actives for their own sake — we make proven actives arrive. The delivery platform is not a marketing layer on top of the serum; it is the reason the serum can work at all.

Every performance number traces back to one physical decision: a shorter, hollower rod. Because 30–70% of the engineered rod is usable internal space versus roughly 3% for a natural spicule, it carries far more active per unit of material. The two-photon imaging made the consequence vivid — an equal delivered dose needed about one-hundredth of the material. We learned that "smaller and hollower" is not a trade-off against strength; it is the source of it. Length keeps the rod above the nerve layer, and the hollow core supplies the payload. The two properties reinforce each other rather than competing.

We learned to be precise about feel. Mild sensation is the micro-spicules doing their work; pain would signal tissue damage, which the length is engineered to avoid by stopping short of the nerve layer. So rather than promise a completely sensation-free experience we cannot guarantee for every individual, we describe what the science supports: a light tingle, no injury, no downtime, and a barrier that recovers within hours. Honesty here is not a compliance box to tick — it is what stops a first-time user from mistaking effectiveness for harm, and it is the difference between a product people trust and one they abandon after a single use.

Clinical credibility erodes the moment a number is attached to the wrong claim. So we hold a discipline that occasionally costs us a punchier sentence: human outcomes are attributed to the institute that measured them, with sample size and period; platform delivery figures are attributed to the manufacturer's material science; and patents are credited to their holder, with EVORÍ building on the estate rather than claiming it as its own. It makes some copy longer and more careful. It also means every figure on these pages can survive scrutiny from a dermatologist, a regulator, or a sceptical customer — which is exactly the audience we are writing for.

Fluorescent and reference models — rutin, DiD, and FITC-tagged peptides — let us prove the delivery mechanism quantitatively before finished-formula human trials. That sequencing matters more than it looks: it isolates the platform's contribution from the formula's, so we can say how much of any result comes from delivery versus chemistry. It is also why we are comfortable publishing platform data now while our own finished-formula clinical program is still running. The mechanism is established; the finished-product efficacy study is the next rung on the same ladder, and we will report it the same way — measured, attributed, and limited to what the data can carry.